DNLI — Denali Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1714899 ·
Last close
$18.00
Market Cap
$2.89B
52W High
$27.30
52W Low
$15.34
ADV30
1,636,320
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 17,778,000 | 17,586,000 | -126,751,000 | 70,126,000 | 1,256,035,000 | 102,870,000 | 329,648,000 |
| Jun 2026 | 3,604,000 | 3,511,000 | -130,541,000 | -127,553,000 | 1,157,955,000 | 201,530,000 | 322,777,000 |
| Mar 2026 | 0 | — | -137,357,000 | -128,447,000 | 1,266,023,000 | 387,626,000 | 339,925,000 |
| Dec 2025 | 0 | — | -137,365,000 | -128,549,000 | 1,144,854,000 | 205,326,000 | 131,093,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-444,187,000
Investing CF
$27,341,000
Financing CF
$428,753,000
CapEx
$-41,805,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.73
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,237,398,000
Inventory
$26,275,000
Receivables
$18,882,000
ST Investments
$413,326,000
EBIT TTM
$-532,014,000
Pretax Income TTM
$-314,321,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$21,382,000
EBITDA
$-513,996,000
Free Cash Flow
$-301,324,256
Enterprise Value
$2,736,076,288
Total Cash
$516,196,000
Total Debt
$35,241,000
Shares Out
160,290,546
Trailing EPS
$-1.72
Book Value
$5.78
ROE
-33.9%
ROA
-28.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -555,342,000 | -512,540,000 | 1,144,854,000 | 131,093,000 | 1,013,761,000 | -412,600,000 |
| Dec 2024 | 0 | -501,878,000 | -422,773,000 | 1,374,180,000 | 144,496,000 | 1,229,684,000 | -347,694,000 |
| Dec 2023 | 330,531,000 | -196,699,000 | -145,224,000 | 1,153,917,000 | 122,963,000 | 1,030,954,000 | -357,991,000 |
| Dec 2022 | 108,463,000 | -340,744,000 | -325,991,000 | 1,460,242,000 | 417,812,000 | 1,042,430,000 | -244,716,000 |
TTM Snapshot
Revenues TTM
$3,604,000
NetIncome TTM
$-511,451,000
OpCashFlow TTM
—
Assets (Latest)
$1,157,955,000
Forward EPS
$-2.27
Max Pain — expiry 2026-12-18
max pain strike: $20.00 · spot: $18.40 · call oi: 2,397 · put oi: 5,300
Expected Move to 2026-12-18:
±$2.92
(15.90%) —
implied range
$15.47 –
$21.32
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VCEL | Vericel Corp | $2.95B | $57.88 | — |
| ADMA | ADMA BIOLOGICS, INC. | $3.02B | $13.63 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.48B | $7.53 | — |
| RLAY | Relay Therapeutics, Inc. | $3.64B | $16.47 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.86B | $78.20 | — |
News headlines (Yahoo Finance, 1h cache)
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
2026-11-13 13:14 · Yahoo
Guggenheim reaffirms top pick in Biotech after Q3 results
2026-11-09 20:26 · Yahoo
Should Earnings Beat Require Action From Denali Therapeutics Stock Investors?
2026-11-06 15:17 · Yahoo
Is Denali Therapeutics (DNLI) Already Priced Right For Its Cash Flow?
2026-11-06 03:22 · Yahoo
Denali Therapeutics (DNLI) Earnings Beat Puts Valuation Back In Focus
2026-11-06 01:19 · Yahoo
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
2026-11-05 18:01 · Yahoo
Denali Therapeutics Inc (DNLI) Q3 2026 Earnings Call Highlights: AVLAYAH Revenue Soars Nearly ...
2026-11-04 17:05 · Yahoo
Denali (DNLI) Q3 2026 Earnings Call Transcript
2026-11-04 15:29 · Yahoo
Denali Therapeutics Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Denali Therapeutics Q3 Earnings Call Highlights
2026-11-04 00:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.